These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12714797)

  • 1. Lack of influence of the apolipoprotein E genotype on the outcome of selegiline treatment in Alzheimer's disease.
    Kálmán J; Juhász A; Rimanóczy A; Palotás A; Palotás M; Szabó Z; Boda K; Márki-Zay J; Janka Z
    Dement Geriatr Cogn Disord; 2003; 16(1):31-4. PubMed ID: 12714797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E genotype and gender influence response to tacrine therapy.
    Farlow MR; Lahiri DK; Poirier J; Davignon J; Hui S
    Ann N Y Acad Sci; 1996 Dec; 802():101-10. PubMed ID: 8993489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
    Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
    Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metrifonate treatment of AD: influence of APOE genotype.
    Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
    Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
    Visser PJ; Scheltens P; Pelgrim E; Verhey FR;
    Dement Geriatr Cogn Disord; 2005; 19(2-3):126-33. PubMed ID: 15627759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
    Sparks DL; Connor DJ; Sabbagh MN; Petersen RB; Lopez J; Browne P
    Acta Neurol Scand Suppl; 2006; 185():3-7. PubMed ID: 16866904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease.
    Aerssens J; Raeymaekers P; Lilienfeld S; Geerts H; Konings F; Parys W
    Dement Geriatr Cogn Disord; 2001; 12(2):69-77. PubMed ID: 11173877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.
    Waring JF; Tang Q; Robieson WZ; King DP; Das U; Dubow J; Dutta S; Marek GJ; Gault LM
    J Alzheimers Dis; 2015; 47(1):137-48. PubMed ID: 26402762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis.
    Kleiman T; Zdanys K; Black B; Rightmer T; Grey M; Garman K; Macavoy M; Gelernter J; van Dyck C
    Dement Geriatr Cogn Disord; 2006; 22(1):73-82. PubMed ID: 16699282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological approaches to the therapy of Alzheimer's disease].
    Gavrilova SI
    Vestn Ross Akad Med Nauk; 2006; (9-10):30-4. PubMed ID: 17111921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol and APOE genotype interact to influence Alzheimer disease progression.
    Evans RM; Hui S; Perkins A; Lahiri DK; Poirier J; Farlow MR
    Neurology; 2004 May; 62(10):1869-71. PubMed ID: 15159498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease.
    Rigaud AS; Traykov L; Latour F; Couderc R; Moulin F; Forette F
    Pharmacogenetics; 2002 Jul; 12(5):415-20. PubMed ID: 12142731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.
    Sjögren M; Hesse C; Basun H; Köl G; Thostrup H; Kilander L; Marcusson J; Edman A; Wallin A; Karlsson I; Troell M; Wachtmaister G; Ekdahl A; Olofsson H; Sandström A; Andreasen N; Minthon L; Blennow K
    J Neural Transm (Vienna); 2001; 108(4):451-8. PubMed ID: 11475012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effect of apolipoprotein e genotype and past fertility on age at onset of Alzheimer's disease in women.
    Corbo RM; Gambina G; Ulizzi L; Monini P; Broggio E; Rosano A; Scacchi R
    Dement Geriatr Cogn Disord; 2007; 24(2):82-5. PubMed ID: 17565217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.
    Farlow MR; Lahiri DK; Poirier J; Davignon J; Schneider L; Hui SL
    Neurology; 1998 Mar; 50(3):669-77. PubMed ID: 9521254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E Gene Polymorphisms Affect the Efficacy of Thiazolidinediones for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Iketani R; Ohno K; Kawasaki Y; Matsumoto K; Yamada H; Kishino S
    Biol Pharm Bull; 2018; 41(7):1017-1023. PubMed ID: 29962398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.
    Risner ME; Saunders AM; Altman JF; Ormandy GC; Craft S; Foley IM; Zvartau-Hind ME; Hosford DA; Roses AD;
    Pharmacogenomics J; 2006; 6(4):246-54. PubMed ID: 16446752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
    Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
    Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study.
    Henderson ST; Poirier J
    BMC Med Genet; 2011 Oct; 12():137. PubMed ID: 21992747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.